Cytokinetics announced that their experimental drug, aficamten, significantly improved exercise capacity for patients with obstructive hypertrophic cardiomyopathy (HCM). The study enrolled 300 patients, and after 24 weeks of treatment, those receiving aficamten showed significant improvements in peak oxygen uptake and met the study’s primary goal. The trial also met all 10 of its secondary endpoints. The company believes that this data is likely enough to win FDA approval for aficamten. However, the future of the drug will depend on whether the company can persuade physicians to prescribe it over Bristol Myers’ Camzyos, the only approved HCM treatment. The full results of the study will be presented at a future medical meeting.
Source link
Cytokinetics’ aficamten helps HCM patients in new study
